• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    EVP, Global Supply Chain Evran Sedat converted options into 1,044 units of Bio-Rad A Common Stock and covered exercise/tax liability with 335 units of Bio-Rad A Common Stock, increasing direct ownership by 47% to 2,233 units (SEC Form 4)

    10/21/25 4:42:00 PM ET
    $BIO.B
    Get the next $BIO.B alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    EVRAN SEDAT

    (Last) (First) (Middle)
    C/O BIO-RAD LABORATORIES, INC.
    1000 ALFRED NOBEL DRIVE

    (Street)
    HERCULES CA 94547

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    EVP, Global Supply Chain
    3. Date of Earliest Transaction (Month/Day/Year)
    10/20/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Bio-Rad A Common Stock 10/20/2025 10/20/2025 M 1,044(1) A $0 2,567.847 D
    Bio-Rad A Common Stock 10/20/2025 10/20/2025 F 335 D $321.9 2,232.847 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Units $0(2) 10/20/2025 10/20/2025 M 1,044 (3) (3) Bio-Rad A Common Stock 1,044 $0 2,088 D
    Explanation of Responses:
    1. Shares of Class A common stock acquired on the vesting of restricted stock units.
    2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
    3. On October 20, 2023, the reporting person was granted 4,176 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
    Remarks:
    /s/ Sedat Evran 10/21/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BIO.B alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIO.B

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BIO.B
    SEC Filings

    View All

    SEC Form 144 filed by Bio-Rad Laboratories Inc.

    144 - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/6/25 4:24:39 PM ET
    $BIO.B

    SEC Form 10-Q filed by Bio-Rad Laboratories Inc.

    10-Q - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

    10/29/25 4:18:31 PM ET
    $BIO.B

    Bio-Rad Laboratories Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BIO-RAD LABORATORIES, INC. (0000012208) (Filer)

    10/29/25 4:16:49 PM ET
    $BIO.B

    $BIO.B
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, President, LSG Barry James sold $214,289 worth of Bio-Rad A Common Stock (700 units at $306.18), decreasing direct ownership by 58% to 510 units (SEC Form 4)

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    11/10/25 4:15:49 PM ET
    $BIO.B

    President & COO Divincenzo Jonathan P. converted options into 1,869 units of Bio-Rad A Common Stock and covered exercise/tax liability with 950 units of Bio-Rad A Common Stock (SEC Form 4)

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    10/28/25 12:29:44 PM ET
    $BIO.B

    EVP, Global Supply Chain Evran Sedat converted options into 1,044 units of Bio-Rad A Common Stock and covered exercise/tax liability with 335 units of Bio-Rad A Common Stock, increasing direct ownership by 47% to 2,233 units (SEC Form 4)

    4 - BIO-RAD LABORATORIES, INC. (0000012208) (Issuer)

    10/21/25 4:42:00 PM ET
    $BIO.B

    $BIO.B
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Element Biosciences and Bio-Rad Partner to Deliver Seamless RNA Sequencing Workflow Between Element's AVITI™ System and Bio-Rad's SEQuoia™ Express and SEQuoia™ Complete Stranded RNA Library Prep Kits

    SAN DIEGO and HERCULES, Calif., Feb. 8, 2023 /PRNewswire/ -- Element Biosciences, Inc. — the developer of an innovative DNA sequencing platform disrupting genomics — and Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostic products, today announced a partnership to demonstrate the capabilities of the Bio-Rad SEQuoia RNA Sequencing Library Preparation portfolio on the Element AVITI™ Benchtop Sequencer. The Element AVITI Sequencing Platform's novel Avidity Sequencing chemistry can be easily adapted for use with the Bio-Rad SEQuo

    2/8/23 8:00:00 AM ET
    $BIO
    $BIO.B
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BIO.B
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bio-Rad Laboratories Inc.

    SC 13G - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/14/24 5:25:27 PM ET
    $BIO.B

    Amendment: SEC Form SC 13G/A filed by Bio-Rad Laboratories Inc.

    SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/12/24 1:27:07 PM ET
    $BIO.B

    Amendment: SEC Form SC 13G/A filed by Bio-Rad Laboratories Inc.

    SC 13G/A - BIO-RAD LABORATORIES, INC. (0000012208) (Subject)

    11/4/24 11:22:04 AM ET
    $BIO.B